Her2/neu Expression in Wilms' Tumor and Correlation With Histopathologic Findings

被引:0
作者
Babashahi, Mashaallah [1 ]
Mehrazma, Mitra [2 ]
Nasiri, Seyed Javad [3 ]
Jalilian, Farid Azizi [4 ]
Rezaei-Tavirani, Mostafa [5 ]
机构
[1] Iran Univ Med Sci, Dept Pathol, Tehran, Iran
[2] Iran Univ Med Sci, Oncopathol Res Ctr, Tehran, Iran
[3] Iran Univ Med Sci, Ali Asghar Children Hosp, Dept Pathol, Tehran, Iran
[4] Ilam Univ Med Sci, Dept Med Microbiol, Ilam, Iran
[5] Shahid Beheshti Univ Med Sci, Prote Res Ctr, Tehran, Iran
关键词
Her2/neu; Wilms' tumor; Nephroblastoma; Tumor component;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Wilms' tumor is an emberyonal tumor arising from remnants of immature renal tissue. Her2/neu is an onco-protein which mediates cellular proliferation, differentiation and survival. Methods: In the current study, we analyzed Her2/neu expression in 40 Wilms' tumors. The clinico-demographic data of 40 patients with Wilms' tumor were retrieved. Immunohistochemical staining for HER2/neu was performed. Her2/neuimmunoreactivity was evaluated by Canadian Consensus 2007 scoring system. Results: Among the 38 specimens with epithelial component, 68.5% were positive for Her2/neu, whereas there was immunoreactivity in 37% of 38 blastemal, and 12% of 31 stromal components. The Her2/neu expression was significantly higher in early stages (81.5%) than in advanced stages (36.4%) in epithelial component, but not in other components. Conclusion: This study suggested that Her2/neuexpression is associated with epithelial cell differentiation accompanied by lower stages of tumor. No significant relationship was found between Her2/neu positivity and tumor size and patient's age and gender.
引用
收藏
页码:160 / 164
页数:5
相关论文
共 18 条
  • [1] Trastuzumab causes antibody-dependent cellular cytotoxicity-mediated growth inhibition of submacroscopic JIMT-1 breast cancer xenografts despite intrinsic drug resistance
    Barok, Mark
    Isola, Jorma
    Palyi-Krekk, Zsuzsanna
    Nagy, Peter
    Juhasz, Istvan
    Vereb, Gyorgy
    Kauraniemi, Paivikki
    Kapanen, Anita
    Tanner, Minna
    Vereb, Gyorgy
    Szollosi, Janos
    [J]. MOLECULAR CANCER THERAPEUTICS, 2007, 6 (07) : 2065 - 2072
  • [2] Beckwith J. Bruce, 1994, P1741
  • [3] EPIDEMIOLOGY OF WILMS-TUMOR
    BRESLOW, N
    OLSHAN, A
    BECKWITH, JB
    GREEN, DM
    [J]. MEDICAL AND PEDIATRIC ONCOLOGY, 1993, 21 (03): : 172 - 181
  • [4] Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab
    Cho, HS
    Mason, K
    Ramyar, KX
    Stanley, AM
    Gabelli, SB
    Denney, DW
    Leahy, DJ
    [J]. NATURE, 2003, 421 (6924) : 756 - 760
  • [5] Ghanem MA, 2001, CANCER-AM CANCER SOC, V92, P3120, DOI 10.1002/1097-0142(20011215)92:12<3120::AID-CNCR10173>3.0.CO
  • [6] 2-2
  • [7] Hanna W, 2007, Curr Oncol, V14, P149, DOI 10.3747/co.2007.131
  • [8] Drug therapy: Trastuzumab - Mechanism of action and use in clinical practice
    Hudis, Clifford A.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (01) : 39 - 51
  • [9] Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment:: The M77001 study group
    Marty, M
    Cognetti, F
    Maraninchi, D
    Snyder, R
    Mauriac, L
    Tubiana-Hulin, M
    Chan, S
    Grimes, D
    Antón, A
    Lluch, A
    Kennedy, J
    O'Byrne, K
    Conte, P
    Green, M
    Ward, C
    Mayne, K
    Extra, JM
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (19) : 4265 - 4274
  • [10] The role of HER-2/neu expression on the survival of patients with lung cancer: a systematic review of the literature
    Meert, AP
    Martin, B
    Paesmans, M
    Berghmans, T
    Mascaux, C
    Verdebout, JM
    Delmotte, P
    Lafitte, JJ
    Sculier, JP
    [J]. BRITISH JOURNAL OF CANCER, 2003, 89 (06) : 959 - 965